GLP-1 Medications and Erectile Dysfunction: What the Research Shows
If you are a man who has started a GLP-1 medication for weight management, or who is considering one, you may be wondering what it might do for your sexual health. It is a reasonable question. Erectil
In this article
*Compounded semaglutide and compounded tirzepatide are not FDA-approved medications. This article is for educational and informational purposes only and does not constitute medical advice. GLP-1 medications are not FDA-approved for the treatment of erectile dysfunction. Always consult a licensed healthcare provider before starting or adjusting any medication. Individual results vary. Care at Prescriva is delivered by independently licensed providers, not by Blue Oak Services LLC dba Prescriva, which is a management services organization.*
---
If you are a man who has started a GLP-1 medication for weight management, or who is considering one, you may be wondering what it might do for your sexual health. It is a reasonable question. Erectile dysfunction and obesity often travel together, and the hope that significant weight loss could improve things below the belt is understandable.
The honest answer is that the research on this specific question is more complicated than you might expect. Weight loss, in general, does appear to benefit erectile function. Whether GLP-1 medications offer that same benefit, and what their direct effects on sexual health might be, is a question scientists are actively working out. Some early findings are reassuring. Others warrant attention.
This article walks through what the evidence actually shows, without overpromising or dismissing a topic that matters to millions of men.
---
Why Obesity and Erectile Dysfunction Are So Often Connected
To understand how GLP-1 medications might affect erectile function, it helps to understand why obesity affects it in the first place.
Erectile function depends on a cascade of events: a stimulus triggers the brain, which signals the nerves, which release nitric oxide into the penile arteries, which dilate to allow blood flow. When that cascade works correctly, erection happens. When any link in the chain is compromised, it does not.
Obesity disrupts this cascade through several pathways:
The vascular pathway. Excess adiposity contributes to endothelial dysfunction, the impaired ability of blood vessels to dilate and constrict properly. This is the same mechanism that drives cardiovascular disease. The penis is highly dependent on healthy vascular function; even modest endothelial damage can impair the blood flow needed for erection. Research consistently finds that ED is a strong predictor of future cardiovascular events, not because ED causes heart disease, but because both share the same underlying vascular pathology.
The hormonal pathway. Adipose tissue converts testosterone to estrogen via an enzyme called aromatase. Men with higher body fat percentages tend to have lower total and free testosterone levels. Testosterone supports libido, energy, and aspects of sexual arousal. When levels fall, sexual motivation and function can decline.
The inflammatory pathway. Obesity is associated with chronic low-grade systemic inflammation. Inflammatory cytokines, particularly TNF-alpha and IL-6, impair nitric oxide production and contribute to vascular dysfunction. This inflammation is one reason metabolic and sexual health problems so often cluster together in men with significant overweight.
The psychological pathway. Body image concerns, reduced physical confidence, depression, and anxiety, each more common in people with obesity, also contribute meaningfully to erectile function through their effects on arousal and performance.
This is not a single-cause problem. It is a convergence of vascular, hormonal, inflammatory, and psychological factors, all of which are influenced by excess body weight.
---
What Weight Loss Does for Erectile Function
If obesity damages erectile function through these pathways, the logical question is whether weight loss reverses the damage. The answer, based on controlled research, is: yes, to a meaningful degree.
One of the clearest studies on this came from a randomized controlled trial published in JAMA in 2004. Researchers in Italy enrolled 110 obese men aged 35 to 55, all of whom had erectile dysfunction at baseline. Half were assigned to an intensive lifestyle intervention focused on diet, physical activity, and weight loss. Half received general health information without structured intervention.
After two years, men in the intervention group lost an average of 33 pounds and saw their International Index of Erectile Function (IIEF) scores improve from 13.9 to 17.0. In the control group, scores barely moved. About one-third of the men in the lifestyle intervention group achieved normal erectile function by the end of the study, compared to just 5 percent of controls (Esposito et al., JAMA, 2004, [PMID: 15213209](https://pubmed.ncbi.nlm.nih.gov/15213209/)).
The improvements in erectile function correlated with reductions in BMI, increases in physical activity, and decreases in inflammatory markers like C-reactive protein. It was not simply the number on the scale that mattered; the physiological changes accompanying weight loss, improved vascular health, lower inflammation, better hormonal balance, appeared to drive the sexual health improvements.
Similar findings emerged from the Look AHEAD trial, a large study examining intensive lifestyle intervention in overweight and obese men with type 2 diabetes. Over the first year, men in the intensive intervention group, who lost nearly 10 percent of their body weight, were significantly more likely to see improvements in erectile function than those in the control group. Twenty-two percent of the intensive intervention group reported improved erectile function, compared with much weaker outcomes in the control arm (Wing et al., Journal of Sexual Medicine, 2010, [PMID: 19694925](https://pubmed.ncbi.nlm.nih.gov/19694925/)).
The takeaway from this body of research: substantial weight loss, achieved through whatever means, tends to improve erectile function in men for whom vascular and hormonal factors are the underlying contributors.
---
---
What GLP-1 Medications Might Do Directly
Given that weight loss helps erectile function, and GLP-1 medications produce significant weight loss, the simple expectation would be: GLP-1 medications should help with ED.
The biology also gives some reasons to expect benefit beyond weight loss alone. GLP-1 receptors are expressed in endothelial tissue, and research in animal models has suggested that GLP-1 receptor activation may have direct favorable effects on vascular function and nitric oxide production. Anti-inflammatory effects of GLP-1 agonists, including reductions in CRP and inflammatory cytokines, are well documented in human trials. Weight loss achieved with semaglutide and tirzepatide is also associated with improvements in testosterone levels in men, which could translate to better libido and sexual function.
These are biologically plausible reasons to expect benefit. But biological plausibility is not the same as clinical proof, and two recent studies have added important complexity to the picture.
---
A Concerning Signal: What the Observational Data Shows
In 2024, researchers published a study using the TriNetX real-world database, examining non-diabetic obese men who were prescribed semaglutide for weight loss versus a matched comparison group (Able et al., International Journal of Impotence Research, 2024, [PMID: 38778151](https://pubmed.ncbi.nlm.nih.gov/38778151/)).
The findings were unexpected. Men on semaglutide had a 4.5-fold higher incidence of newly diagnosed erectile dysfunction or initiation of PDE5 inhibitor therapy (1.47 percent versus 0.32 percent). They also had nearly double the rate of testosterone deficiency diagnosis (1.53 percent versus 0.80 percent).
This is an observational study, not a randomized trial, which means it cannot establish that semaglutide caused the ED. Men who seek prescription weight management medications may differ from controls in ways that are difficult to fully account for in database studies. Surveillance bias is also possible: men in more active medical care may simply be more likely to have ED diagnosed.
Separately, a 2026 target trial emulation study using claims data found a modestly elevated hazard ratio for erectile dysfunction among men with type 2 diabetes starting GLP-1 receptor agonists versus DPP-4 inhibitors. But the authors found the association weakened substantially after statistical calibration for unmeasured confounding, and they concluded the findings did not establish causation (Tang et al., eClinicalMedicine, 2026, [PMID: 42005929](https://pubmed.ncbi.nlm.nih.gov/42005929/)).
These studies do not prove that GLP-1 medications harm erectile function. But they add nuance to a narrative that had assumed the medications would clearly help. The weight loss achieved may benefit ED through vascular and hormonal improvements, while the medication's direct effects on testosterone levels and sexual function may be more complicated, particularly early in treatment.
One hypothesis worth noting: the caloric restriction accompanying GLP-1-driven weight loss, especially rapid or steep initial restriction, can transiently lower testosterone in some men. This is a known phenomenon in the weight loss research literature, not unique to GLP-1 medications, and it may partially explain some of the observations.
---
What This Means for Men Considering or Already Taking GLP-1 Medications
The research does not support avoiding GLP-1 medications over concerns about sexual function. Cardiovascular risk reduction, glycemic improvement, weight loss, and the broad metabolic benefits of these medications remain well established and clinically meaningful.
But men who notice changes in libido, erectile function, or energy during GLP-1 treatment should raise this with their provider rather than dismissing it or simply stopping their medication. This is exactly the kind of clinical observation that helps providers tailor treatment, check testosterone levels if appropriate, and address contributing factors.
A few practical points worth knowing:
Testosterone levels can be monitored. If you are on a GLP-1 medication and experiencing changes in sexual function, your provider can check a testosterone panel. If levels are low, that is a manageable clinical issue, not a reason to stop weight management treatment.
Weight loss benefits take time. The cardiovascular, vascular, and hormonal benefits of significant weight loss, the mechanisms most likely to improve erectile function, generally accumulate over months, not weeks. Early in treatment, when metabolic adaptations are still underway, sexual function may not yet reflect the longer-term benefits of improved body composition.
ED has multiple causes. In men where psychological factors, relationship stress, performance anxiety, or sleep disorders are primary contributors to ED, GLP-1-driven weight loss will have limited impact on those factors unless they are also addressed directly.
GLP-1 medications are not an ED treatment. Compounded semaglutide and tirzepatide are not FDA-approved for erectile dysfunction, and they should not be used or marketed for that purpose. If ED is a primary concern, there are evidence-based, FDA-approved treatment options including PDE5 inhibitors and other interventions that your provider can discuss with you.
---
The Bottom Line
Obesity and erectile dysfunction are deeply connected through shared pathways in vascular health, hormonal balance, and systemic inflammation. The research on weight loss and erectile function is clear: meaningful weight loss, particularly when accompanied by improved physical fitness and reduced inflammation, tends to improve sexual function in men who have obesity-related ED.
Whether GLP-1 medications provide additional benefit beyond weight loss, or whether they introduce some independent complexity for certain men, is a question that observational research has flagged but that randomized trials have not yet definitively answered. Men who notice changes in sexual function during GLP-1 treatment have legitimate questions worth raising with their healthcare provider.
The right response to this nuance is not alarm. It is an open conversation with the clinical team managing your care.
---
*This article is for educational purposes only and does not constitute medical advice. Compounded semaglutide and tirzepatide are not FDA-approved medications and are not approved for the treatment of erectile dysfunction. Results vary by individual. Always consult a licensed healthcare provider before starting, stopping, or modifying any medication.*
---
Citations:
- Esposito K, et al. "Effect of lifestyle changes on erectile dysfunction in obese men: a randomized controlled trial." JAMA. 2004. [PMID: 15213209](https://pubmed.ncbi.nlm.nih.gov/15213209/)
- Wing RR, et al. "Effects of weight loss intervention on erectile function in older men with type 2 diabetes in the Look AHEAD trial." Journal of Sexual Medicine. 2010. [PMID: 19694925](https://pubmed.ncbi.nlm.nih.gov/19694925/)
- Able C, et al. "Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study." International Journal of Impotence Research. 2024. [PMID: 38778151](https://pubmed.ncbi.nlm.nih.gov/38778151/)
- Tang H, et al. "GLP-1 receptor agonist and risk of erectile dysfunction in men with type 2 diabetes: a target trial emulation." eClinicalMedicine. 2026. [PMID: 42005929](https://pubmed.ncbi.nlm.nih.gov/42005929/)
Stay informed
Weekly research updates and health guides. No spam.
Ready to get started?
Check if you qualify for a personalized treatment plan.
Check Your Eligibility →Continue reading
Does Semaglutide Cause Thyroid Cancer? What the Research Actually Shows
Semaglutide Nausea: Why It Happens and How to Manage It
